Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: Provider of innovative tools for drug discovery research, focusing on target validation, assay development, and ADMET screening. The company operates globally with manufacturing and sales in the U.S., U.K., and Germany.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|---|---|---|---|
| Total Revenues | $13,729 | $25,692 | $18,318 |
| Net Income (Loss) | $1,018 | $1,791 | $(5,093) |
| Operating Income (Loss) | $1,485 | $2,667 | $(4,802) |
| Cash and Equivalents | $27,025 (Balance Sheet) | Decreased $2,361 from Dec 31, 2001 | |
| Net Cash from Operations | $920 (Six Months) | $2,668 | |
| Total Debt (Current + Long-term) | $798 | Significant reduction from $4,531 at Dec 31, 2001 | |
| Goodwill | $20,757 | No amortization recorded under SFAS 142 |
Margins (Six Months 2002):
- Gross Margin (Product): Approximately 50.2% (Derived from Product Revenue $24,893 and Cost $12,405)
- Operating Margin: 10.4%
- Net Margin: 7.0%
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 41% ($4.0M) for the quarter and 40% ($7.4M) for the six months compared to 2001. Growth was driven by acquisitions made in 2001 (contributing ~19-23% of the increase) and organic growth from new product lines (spectrophotometers, plate readers).
- Profitability Turnaround: The company reported a net income of $1.0M for the quarter and $1.8M for the six months, a significant improvement from a net loss of $5.4M and $5.1M, respectively, in the prior year periods. This turnaround is largely due to the absence of $5.4M in in-process research and development (IPR&D) expenses recorded in 2001 upon acquisition.
- Expense Management: Stock compensation expense decreased significantly to $331,000 (quarter) and $655,000 (six months) from $779,000 and $1,541,000 in 2001. General and administrative expenses increased in absolute terms but decreased as a percentage of revenue (15.5% vs 19.2% for the quarter) due to operating leverage.
- Debt Reduction: Total debt decreased substantially as the company repaid approximately $3.7 million in debt related to the SciePlas Ltd. acquisition.
- Accounting Changes: Adoption of SFAS No. 142 eliminated goodwill amortization effective January 1, 2002, improving reported earnings.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
Management expects available cash and operating cash flows to be sufficient to finance operations and capital expenditures for the foreseeable future. However, the company may need to raise additional capital to accelerate product development or make further acquisitions, which could dilute existing shareholders.
Subsequent Events:
- Acquisition: On July 1, 2002, the Biochrom subsidiary acquired Walden Precision Apparatus for approximately $1.4 million.
- Merger Agreement: On July 17, 2002, the company entered into a merger agreement to acquire Genomic Solutions Inc. for $9 million in cash and 3.2 million shares of common stock.
Risks and Contingencies:
- Legal Proceedings: Harvard University is suing for trademark infringement regarding the names "Harvard Bioscience" and "Harvard Apparatus." While a preliminary injunction was denied and a partial summary judgment was issued in the company's favor regarding "Harvard Apparatus," the litigation continues.
- Arbitration: Former owner Paul D. Grindle initiated arbitration seeking the return of ~1.56 million shares or $15 million in damages related to a 1996 asset purchase. The company believes these claims are without merit.
- Foreign Currency: Results are affected by exchange rate fluctuations. The company does not currently hedge but matches assets and liabilities to manage risk.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 40% revenue growth, distinguishing between organic growth and the one-time impact of 2001 acquisitions.
- Legal Exposure: Monitor the status of the Harvard University trademark lawsuit and the Paul Grindle arbitration, as adverse outcomes could result in significant financial liability or brand restrictions.
- Merger Impact: Assess the financial implications and integration risks of the pending Genomic Solutions merger announced in July 2002.
- Cash Flow Trends: Review the decline in operating cash flow ($2.7M in 2001 to $0.9M in 2002) driven by increased accounts receivable and working capital needs.
- Debt Obligations: Confirm the repayment schedule for remaining debt and the impact of the new acquisition financing on liquidity.